Brevan Howard Capital Management LP lowered its position in shares of Henry Schein, Inc. (NASDAQ:HSIC – Free Report) by 22.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,224 shares of the company’s stock after selling 12,453 shares during the period. Brevan Howard Capital Management LP’s holdings in Henry Schein were worth $2,869,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. CYBER HORNET ETFs LLC bought a new position in Henry Schein during the 2nd quarter worth about $25,000. MUFG Securities EMEA plc purchased a new position in Henry Schein during the 2nd quarter valued at about $27,000. Sentry Investment Management LLC raised its holdings in shares of Henry Schein by 132.1% in the 3rd quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock valued at $59,000 after purchasing an additional 515 shares in the last quarter. Evelyn Partners Investment Management Services Ltd purchased a new stake in shares of Henry Schein in the 2nd quarter worth approximately $62,000. Finally, Mather Group LLC. purchased a new stake in shares of Henry Schein in the 3rd quarter worth approximately $71,000. 96.62% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, Director Kurt P. Kuehn sold 2,844 shares of the firm’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $78.96, for a total value of $224,562.24. Following the completion of the sale, the director owned 15,420 shares of the company’s stock, valued at $1,217,563.20. This trade represents a 15.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Mark E. Mlotek sold 5,925 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the transaction, the executive vice president owned 80,554 shares in the company, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 104,556 shares of company stock worth $8,476,351. 1.14% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Henry Schein Trading Down 1.3%
NASDAQ HSIC opened at $74.61 on Tuesday. The company has a quick ratio of 0.76, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The firm has a market cap of $8.56 billion, a PE ratio of 22.82, a price-to-earnings-growth ratio of 2.24 and a beta of 0.87. The company has a 50 day moving average price of $78.13 and a 200 day moving average price of $72.93. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the prior year, the company posted $1.19 earnings per share. Henry Schein’s revenue for the quarter was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, sell-side analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.
About Henry Schein
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Stories
- Five stocks we like better than Henry Schein
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC – Free Report).
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
